Furthermore, we were interested to find that amantadine, a prophylactic agent approved by the US FDA in 1968 for influenza and later for Parkinson’s disease, has been reported to suppress the gene transcription of CTSL. 19 We next examined the impact of amantadine on SARS-CoV-2 infection and found that it significantly inhibited pseudovirus infection with little cytotoxicity (Fig. 5d). The gene discussed is CTSL; the disease is Parkinson disease.